Impact Biomedical (IBO) Restructuring Costs (2022 - 2023)
Impact Biomedical's (IBO) quarterly Restructuring Costs came in at $122000.0 in Q4 2023, up 335.71% on a YoY basis from $28000.0 in Q4 2022, and up 430.43% quarter-over-quarter from $23000.0 in Q3 2023.
Powered by 
Analysis
Impact Biomedical (IBO) Restructuring Costs (2022 - 2023) Analysis & Trends
Impact Biomedical (IBO) has reported Restructuring Costs for 2 consecutive years, with $122000.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Restructuring Costs rose 335.71% year-over-year to $122000.0; the trailing twelve-month figure through Dec 2023 stood at $187000.0 (changed N/A YoY), and the FY2023 full-year result was $184000.0, up 170.59% from the prior year.
- Restructuring Costs grew to $122000.0 in Q4 2023 per IBO's latest filing, from $23000.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $122000.0 in Q4 2023 and bottomed at $7000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 122,000.00 |
| Sep 30, 2023 | 23,000.00 |
| Jun 30, 2023 | 14,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 29,000.00 |